Company: DNLI
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001714899-25-000170
Chunk: 199

Company: Denali Therapeutics Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 199
---
 lease$2,948 $2,854 $5,833 $5,647 As of June 30,20252024Weighted-average remaining lease term (in years):Operating lease3.8 years4.8 yearsFinance lease13.8 years—Weighted-average discount rate applied (%):Operating lease9.0%9.0%Finance lease13.7%—%

16

The following table reconciles the undiscounted cash flows for the next five years and total of the remaining years to the operating and finance lease liabilities recorded in the Condensed Consolidated Balance Sheet as of June 30, 2025 (in thousands):Year Ended December 31:Operating LeaseFinance Lease2025 (six months)$5,960 $1,736 202612,182 794 202712,584 811 202813,001 829 20294,381 848 Thereafter— 8,814 Total undiscounted lease payments48,108 13,832 Less: present value adjustment(7,127)— Less: imputed interest— (6,840)Total future minimum lease payments$40,981 $6,992 

IndemnificationIn the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations and Comprehensive Loss, or Condensed Consolidated Statements of Cash Flows.

CommitmentsEffective September 2017, the Company entered into a Development and Manufacturing Services Agreement as amended (“DMSA”) with Lonza Sales AG (“Lonza”) for the development and manufacture of biologic products. Under the